Atossa CEO Steven Quay to Join Harvard Panel on Aging Research
As the global search for therapies targeting aging-related diseases accelerates, Atossa Therapeutics CEO Dr. Steven Quay will join a panel of experts at Harvard University to dissect the complexities of clinical trial design and the evolving regulatory landscape required to bring new treatments to patients.
The discussion is set for October 1 at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), hosted at the David Rubenstein Treehouse in Boston. Dr. Quay will share the stage with leaders from Novo Nordisk, Mass General Brigham, and UCLA to address how scientific discoveries in aging biology translate into viable clinical programs. Sebastien Thuault, an editor at Nature Medicine, will moderate the session.
For Atossa, the event highlights a strategic pivot toward integrating rigorous biological evidence with clear regulatory pathways, particularly as the firm expands its research into rare diseases. Central to the company’s current portfolio is (Z)-endoxifen, a proprietary selective estrogen receptor modulator currently undergoing evaluation for various oncological and rare disease applications. By participating in the ARDD forum, the company aims to align its ongoing development of (Z)-endoxifen with broader industry standards for clinical endpoints and therapeutic efficacy.
Comments (0)
No comments yet. Be the first!